Kornimate/medical-research-clean huggingface dataset:
the effects of cilnidipine on metabolic syndrome improvement

Conditions: Hypertension; Metabolic Syndrome X

Summary: abnormalities of glucose, insulin and lipoprotein metabolism are common in patients with hypertension, and these metabolic abnormalities are reported to be related to insulin resistance. therefore, whenever treating such patients, antihypertensive agents that may have the added effect of improving insulin resistance should be selected. cinalongtm (cilnidipine) is expected to improve metabolic syndrome as well as insulin resistance by its dual effects on l and n-type calcium (ca) channels. in this study, the researchers investigate the effects of cinalongtm on insulin resistance and other metabolic related factors.

* multi-center, randomized, prospective, double blind, active control, parallel study * superiority study (treatment group - cilnidipine/control group - nifedipine) * measure the effects of cinalong(tm) after 3 month and 12 month-application

Eligibility criteria:
inclusion criteria: 1. men or women, 30-65 years of age having essential hypertension with metabolic syndrome 2. at screening and visit 1, blood pressure should be: sitting systolic blood pressure (sisbp) \>=140 mmhg or sitting diastolic blood pressure (sidbp)\>= 90 mmhg and two or more of the following criteria should apply. * abdominal obesity: waist circumference \>= 90 cm in men and \>= 80 cm in women * hypertriglyceridemia:. \>=150 mg/dl (1.695 mmol/l) * low hdl cholesterol: \< 40 mg/dl (1.036 mmol/l) in men and \< 50 mg/dl (1.295 mmol/l) in women * high fasting glucose: \>= 110 mg/dl (6.1 mmol/l) exclusion criteria: 1. secondary hypertension 2. malignant hypertension

Keywords: metabolic syndrome hypertension ccb cilnidipine
glucose disturbances in premature infants and quality of life

Conditions: Neonatal Hypoglycemia; Neonatal Hyperglycaemia

Summary: the aim of this study is to investigate the correlation between preterm birth, glucose level in the first two hours of life and health related quality of life in the age of 8 months and 7 years

all premature infants treated from august 2013-august 2014 in two neonatal intensive care units (nicus) are included in this study. glucose levels was analyzed two hours after birth. in the age of 8 months parents completed the questionnaire pediatric quality of life - infant scale. the questionnaire quality of life for children 5-7 years and for their parents will be offered to them in the next 4 months. we will investigate if there is a correlation between glucose levels and quality of life in premature infants, and if quality of life changes over years.

Eligibility criteria:
inclusion criteria: all premature infants treated in two neonatal intensive units in clinical hospital centre rijeka in the year 2013.- 2014. to reach to final outcome, all questionnaires must be completed. - exclusion criteria: all deceased premature children born in the study period. -

Keywords: preterm birth, hypoglycemia, hyperglycemia, quality of life
noninvasive ventilation on chronic obstructive pulmonary disease (copd) patient functionality

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: on the following tests, there would be a greater increase in the functionality of copd patients who underwent combined therapy than in those who only exercised: a set of activities of daily living (adls), the six-minute walk test (6mwt), an incremental symptom-limited cardiopulmonary test (cpt), and the physical functioning scale of the short-form 36 quality of life questionnaire (sf-36).

impact of aerobic exercise plus noninvasive ventilation (niv) on the functionality of patients with copd. thirty patients (70.5 - 8.5 years) with copd (forced expiratory volume in the first second 48.5 - 15.4% of predicted) were randomized into either a physical training group involving aerobic treadmill exercise (ptg, n=12) or an exercise plus bilevel ventilation group (ptgniv, n=11) with sessions three times a week for six weeks.

Eligibility criteria:
inclusion criteria: * copd diagnosis * with a forced expiratory volume in the first second (fev1)/forced vital capacity (fvc)\<70% * clinical stability in the previous two months (i.e., no exacerbation of the disease). exclusion criteria: * decompensated heart failure or rheumatic, orthopedic or neuromuscular diseases that prevented the subjects from performing the tests due to exercise limitations; * participation in a regular physical exercise program at the beginning of the study; * noncompletion of one of the tests or the established protocol for any reason.

Keywords: aerobic exercise noninvasive ventilation functionality
gargling and nasal rinses to reduce oro- and nasopharyngeal viral load in patients with covid-19

Conditions: COVID-19

Summary: for this study, 48 patients who have been diagnosed with covid-19 will be randomly assigned to four study groups: control, saline, chlorhexidine gluconate, and povidone-iodine. each patient will be asked to gargle with a solution of either saline, chlorhexidine gluconate, or povidone-iodine or nothing (control group) as well as spray the same solution in their nose four times daily. patients will then be tested for covid-19 once daily in the evening for 7 days and viral loads will be measured.

covid-19 has emerged as a worldwide pandemic and there is a strong need for identification of any measures that can be used to treat this illness or reduce its transmission from person to person. povidone-iodine has been shown to have virucidal properties against multiple viruses including against the virus that causes sars which is very similar in makeup to the virus causing covid-19. the investigators hypothesize that 4x daily use of oral gargles and nasal rinses using a povidone iodine solution will help to reduce the viral load in the nasopharynx and oropharynx in patients who are covid-19+. if this hypothesis is shown to be true this could potentially have an impact on time to recovery of clinical symptoms as well as reduce shedding of the virus by infected patients. a time course of 7 days was chosen in order to recognize a trend in the viral load over time for patients receiving each of the interventions. chlorhexidine gluconate and saline rinses were chosen as additional treatment arms as these are frequently used for oral and nasal hygiene and their role in affecting viral load is currently unknown.

Eligibility criteria:
inclusion criteria: 1. positive test for covid-19 2. age 18-79 years 3. willing and able to perform oral gargles and nasal rinses four times daily exclusion criteria 1. requiring mechanical ventilation 2. unable or unwilling to perform oral gargles and nasal rinses four times daily 3. history of chronic upper respiratory tract disease 4. known iodine allergy 5. history of thyroid disease
the impact of clavicular length restoration in the treatment of non-unions of clavicular midshaft and lateral fractures

Conditions: Clavicular Length

Summary: evaluating the impact of plate treatment and cortical bone grafting of clavicular midshaft and lateral non- unions on restoration of clavicular length and bony healing and its association with functional outcome.


Eligibility criteria:
inclusion criteria: * clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting * minimal follow- up of two years after surgery * written informed consent exclusion criteria: * legal incompetence * non- union of pathologic fractures * current pregnancy * german language barrier to complete questionnaires

Keywords: clavicle non-unions plate treatment of clavicular fractures cortical bone grafting of clavicular fractures clavicular midshaft non- union clavicular lateral non- union clavicular shortening
cardiovascular risk in digital osteoarthritis

Conditions: Osteoarthritis Hand; Lumbago; Osteoporosis; Radiculopathy Lumbar

Summary: the goal of this cross-sectional case control study is to investigate the cardiovascular risk in digital osteoarthritis. this study aims to compare the cardiovascular risk between group of patients with digital osteoarthritis and control group of patients with non-osteoarthritis disease paired by measurement of carotid intima-media thickness. all participants will undergo an ultrasound scan to measure carotid intima media thickness, a clinical assessment with the rheumatologist and a cardiovascular risk assessment.


Eligibility criteria:
inclusion criteria: for all subjects: * adult male or female subject * able to give informed consent to participate in research * affiliated with a social security plan for the digital osteoarthritis group: * consultant in rheumatology at clermont-ferrand university hospital * affected by digital osteoarthritis meeting acr diagnostic criteria with radiographic signs of osteoarthritis validated by a radiologist. for the control group : * rheumatology consultant at the clermont-ferrand university hospital or hospitalized in this department for a non-arthritic, non-rheumatic pathology. * patients with spinal disc pathology (lumbago, radiculalgia due to disco-radicular conflict) or non-severe osteoporosis, i.e. with a densitometric t score between -2.5 and -3 ds. exclusion criteria: for all topics : * refusal to participate * pregnant women, nursing mothers * subjects under guardianship or curatorship, deprived of liberty, or under court protection for the digital osteoarthritis group: - existence of diagnostic arguments for another inflammatory rheumatism (rheumatoid arthritis, spondylarthritis, psoriatic arthritis, lupus, gout, chondrocalcinosis...) or another arthrosic localization (gonarthrosis, coxarthrosis, discarthrosis) symptomatic at the time of inclusion or affecting daily activities. for the control group : * existence of chronic inflammatory rheumatism (rheumatoid arthritis, spondylitis, psoriatic arthritis, lupus, gout, chondrocalcinosis...) * existence of digital osteoarthritis * existence of another painful arthritic site (knee, hip, rachi) existence of finger pain, whatever the etiology.
a study of imvotamab monotherapy and in combination in subjects with relapsed/refractory non-hodgkin lymphoma

Conditions: Non-Hodgkin Lymphoma; Follicular Lymphoma; DLBCL; Mantle Cell Lymphoma; Marginal Zone Lymphoma

Summary: this is a phase 1/2 study of imvotamab in adult subjects with relapsed or refractory b-cell non-hodgkin lymphoma. this study will consist of a dose-escalation stage, a combination stage, and a randomized dose-expansion stage where subjects will be enrolled into indication-specific expansion cohorts. imvotamab will be administered intravenously (iv). additional cd20-positive nhl histologies (e.g. mzl and mcl), may be allowed with medical monitor approval during the dose-escalation phase of the study.

imvotamab is an engineered bispecific igm antibody for the treatment of patients with cd20-positive cancers. it contains ten high affinity binding domains for cd20, and one binding domain for cd3. imvotamab is able to eliminate cd20-positive lymphoma cells by engaging t-cells and lymphoma cells, leading to t-cell dependent cellular cytotoxicity. additionally, imvotamab is also able to eliminate lymphoma cells by recruiting complement to the surface of lymphoma cells, leading to complement dependent cytotoxicity. in our preclinical studies, we observed activity against rituximab resistant cells carrying low levels of cd20. we have also observed much lower cytokine release with imvotamab relative to comparable igg format bispecific t-cell engaging antibodies, which is expected to result in reduced risk of the serious adverse effects from cytokine release syndrome (crs). for the combination stage, imvotamab will be combined with loncastuximab tesirine, a cd19-targeting antibody drug conjugate.

Eligibility criteria:
key inclusion criteria: * \> 18 years of age: ecog ps 0 or 1 * relapsed or refractory follicular lymphoma (fl), and diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), marginal zone lymphoma (mzl) in dose escalation * relapsed or refractory to at least two prior systemic treatment regimens (must include anti-cd20 chemo-immunotherapy regimen). fl/mzl may be enrolled with a least 2 prior systemic regimens which must include an anti-cd20, without the need for a prior chemotherapy regimen) * at least one bi-dimensionally measurable lesion (\>1.5cm in it's longest dimension by computerized tomography (ct scan) * good organ function * not eligible for autologous stem cell transplant (dlbcl subjects), due to chemoresistant disease, medically unfit (organ function), or unwilling. key exclusion criteria: * prior allogeneic transplant * asct within 100 days prior to the first imvotamab administration. * lack of response to prior treatment with car-t therapy, subjects with less than 3 months from prior car-t therapy to first dose of imvotamab, and prior car-t therapy only allowed with medical monitor approval. * concurrent serious co-morbidities that could limit patients full participation and compliance. * prior cd-targeting bispecific antibodies. * prior loncastuximab tesirine.

Keywords: lymphoma non-hodgkin lymphoma dlbcl follicular lymphoma relapsed or refractory
safety and efficacy study of brimonidine/timolol fixed combination in patients with glaucoma or ocular hypertension

Conditions: Ocular Hypertension

Summary: the purpose of this study is to assess the safety and efficacy of brimonidine/timolol fixed combination in patients with glaucoma or ocular hypertension


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes * patient requires iop-lowering drug in both eyes exclusion criteria: * uncontrolled medical condition * contraindication to beta-adrenoceptor antagonist or brimonidine therapy
patient interview study to explore the impact of gene therapy in hemophilia a & b

Conditions: Hemophilia A; Hemophilia B

Summary: the purpose of this study is to learn about experiences of patients with hemophilia a and b after taking gene therapy. the experiences of patients will be studied through online interviews. this study is seeking participants who are: * part of the pfizer's gene therapy clinical studies or * in the long-term follow up for these clinical programs. participants will have one study visit at the clinic and one online interview. the planned duration for each participant will be 1 to 2 months. this covers the time from entering the study to end of the online interview.


Eligibility criteria:
inclusion criteria: * participation in the pfizer's gene therapy clinical trials for hemophilia a or b . * participants will be one year or more post-gene therapy * participants will be willing to provide written consent and will be willing to comply with the study requirements exclusion criteria: -no exclusion criteria

Keywords: hemophilia a hemophilia b genetic therapy
pulse pressure variability with position before epidural analgesia

Conditions: Labor; Epidural Analgesia

Summary: fetal heart rate abnormalities are common. miller et al. have demonstrated that new onset fetal heart rate abnormalities after initial labor epidural dosing occur more frequently in women with a low admission pulse pressure than those with a normal admission pulse. the aim of the present study is to look for a statistical link between the occurrence of a fetal heart abnormality requiring an intervention and maternal hemodynamic factors (blood pressure, pulse pressure, and cardiac output) measured before epidural analgesia in two positions: dorsal decubitus position and in the left lateral decubitus.


Eligibility criteria:
inclusion criteria: * pregnant women * gestational age ≥ 36 weeks * single eutrophic fetus * wishing for epidural analgesia * cervical dilatation less than or equal to 5 cm * spontaneous labor * scheduled for a vaginal delivery. non-inclusion criteria: * prematurity (\< 36 weeks of amenorrhea) or post-term birth * intention of induction of labour using oxytocin before epidural analgesia or prostaglandin * contraindication to epidural analgesia * history of hypertension or gravidic hypertension or heart disorder * gestational diabetes * foetal malformation or oligohydramnios or fetal growth abnormality * fœtal macrosomia diagnosed by ultrasonic scanning * hematocrit less than 20% exclusion criteria * induction of labour using oxytocin before epidural analgesia * newborn weight \> 4kg at birth

Keywords: fetal heart rate abnormalities pregnancy epidural analgesia pulse pressure
b7 coreceptor molecules in hyper igd syndrome form of mevalonate kinase deficiency

Conditions: Hyper IgD Syndrome; Mevalonate Kinase Deficiency

Summary: the hyper igd syndrome (hids) is an inflammatory disease caused by mevalonate kinase deficiency. there is no cure, and available treatments of hids febrile episodes have shown limited clinical efficacy. the development of effective interventions for hids is limited by our poor understanding of the disease. the goal of the study is to better characterize the inflammatory response during hids episodes and to determine the relationship between this response and blood and urine markers of mevalonate kinase deficiency. this knowledge will help us learn more about the cause of the disease and should lead to the identification of new disease biomarkers that can be used to evaluate clinical efficacy in future therapeutic trials. the primary hypothesis is that the costimulatory b7 glycoprotein abnormalities identified in the murine mkd model will be recapitulated in sera obtained from human hids patients, either before, during or after febrile episodes. the secondary hypothesis is that b7 glycoprotein molecule levels will correlate with clinical symptomatic severity score, other known biomarkers of hids, markers of inflammation and or markers of isoprenoid metabolism.


Eligibility criteria:
inclusion criteria: * any race or ethnicity * diagnosed with hids exclusion criteria: * parents' inability to donate blood * currently having cancer, renal failure, diabetes, liver disease, thyroid diseases, major infectious diseases or immunodeficiency * pregnancy * inability to provide consent

Keywords: hyper igd syndrome (hids) mevalonate kinase deficiency (mkd)
safety, tolerability,and adherence to co-formulated tenofovir-emtricitabine-rilpivirine used as hiv nonoccupational post-exposure prophylaxis in men who have sex with men.

Conditions: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men

Summary: this study aims to describe the safety, tolerability and adherence to the coformulated anti-hiv drug tenofovir-emtricitabine-rilpivirine (eviplera) when given to men who have sex with men (msm) following an actual or potential sexual exposure to hiv. this biomedical intervention is known as nonoccupational post-exposure prophylaxis (npep). patients receive npep if they meet the criteria outlined in the 2007 national australian npep guidelines. three or two anti-hiv drugs are administered for 28-days depending on the severity of the the assessed hiv acquisition risk. in this study eviplera would constitute 3-drug npep. tenofovir-emtricitabine (truvada) a component of eviplera has been used in npep at svh since 2006. this is a multi site, prospective, open-label, non-randomised trial. participants will be msm who present at the various recruitment sites requesting npep. initially, 50 eligible participants will be assigned to receive eviplera 25mg once daily taken with food for 28-days according to established australian guidelines for the use of 3-drug npep. there will be 7 visits over a 12-week period. follow-up post npep is for 8 weeks. if an interim analysis demonstrates acceptable safety, it is proposed to seek ethics approval to increase the samples size to 100 patients to gain more accurate information on regimen completion rate and on-drug adherence. the primary study objectives are: 1. to describe the safety of 28 days of npep using co-formulated ftc-rpv-tdf 2. to describe the tolerability of 28 days of npep using ftc-rpv-tdf 3. to describe on-drug adherence and regimen completion rates of 28 days of npep using ftc-rpv-tdf


Eligibility criteria:
inclusion criteria: 1. man who has sex with men 2. age at least 18 years 3. eligible for 3-drug npep according to australian guidelines for the use of 3-drug npep following an actual or potential sexual exposure to hiv or receptive anal intercourse with an unknown source 4. able to provide written, informed consent 5. able to commit to the study visits exclusion criteria: 6. non-sexual exposure 7. exposure occurring during sex between a man and a woman 8. hiv infection diagnosed on day 1 serological testing including indeterminate serology consistent with possible primary hiv infection 9. use of any medication contraindicated with ftc-rpv-tdf 10. serum hepatic transaminase (alanine aminotransferase \[alt\] greater than 5 times the upper limit of the normal range 11. serum estimated glomerular filtration rate (egfr) \<60ml/min/ bsac 12. current therapy for hepatitis b 13. day 1 serological evidence of chronic/active hepatitis b 14. previous npep containing ftc-rpv-tdf 15. a patient with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study
effect of transcutaneous electrical nerve stimulation on cognition in multiple sclerosis patients

Conditions: Multiple Sclerosis; Cognitive Disorders

Summary: the aim of this study is to evaluate whether the transcutaneous electrical nerve stimulation (tens) is effective on improvement of cognitive disorders in multiple sclerosis patients.

multiple sclerosis (ms) is one of the most common autoimmune diseases in the world. one of the complications of ms, is cognitive disorder. in some studies on rats, stimulation of somatosensory neurons has improved the hippocampus activity by increasing the amount of acetylcholine. hippocampus has a major role in cognition and behavior. tens is a non-invasive method in which the electrical pulses are sent to the body trough skin by electrodes. this device can stimulate the somatosensory neurons by electrical impulses. in several studies, the effect of tens has been proved on short term memory and verbal fluency in patients with mild stages of alzheimer disease. also it has been effective on some aspects of cognition on old people suffering from forgetfulness.

Eligibility criteria:
inclusion criteria: * patients with confirmed multiple sclerosis by mcdonald criteria; * score 25 or less in mini mental state examination (mmse) exclusion criteria: * mmse score greater than 25; * the history of psychiatric problems; * addiction to alcohol; head trauma; cerebrovascular disease; hydrocephalus; neoplasm; epilepsy; renal or respiratory diseases; impaired consciousness
yoga for patients with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the proposed study aims to investigate the feasibility, effectiveness, and perceived benefit of a hatha yoga intervention for patients with irritable bowel syndrome (ibs) compared to nutrition counselling. further, the potential of both interventions to influence the gut microbiome will be inquired.


Eligibility criteria:
inclusion criteria: * patients with irritable bowel syndrome (ibs) diagnosed by physician and confirmed by rome iii diagnostic criteria exclusion criteria: * inflammatory bowel diseases (ibd) * total abdominal colectomy * no sonographie or colonoscopy as diagnostic criterion * stool lactoferrin \> 7mg/g * pregnancy or breast feeding * simultaneous participation in further clinical intervention trials * regular yoga practice or nutrition counselling in the past 12 months * planned surgery in the study period * serious illness that would interfere with the ability to practice yoga